Related Experiment Video
Updated: Sep 16, 2025
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
18.4K
Cryogel-Based Dendritic Cell Immunotherapy for Post-Surgical Breast Cancer Treatment
Lam-Duc-Huy Nguyen1,2, Sheng-Liang Cheng1,3, Yu-Ting Yen4
1Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu, 30013, Taiwan.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|July 11, 2025
Summary
This study introduces a novel cryogel immunotherapy combining dendritic cells (DCs), doxorubicin, and immune checkpoint blockade to boost anti-tumor immunity after surgery for triple-negative breast cancer (TNBC). The treatment effectively reduces recurrence, metastasis, and prolongs survival in TNBC models.
Area of Science:
- Oncology
- Immunotherapy
- Biomaterials Science
Background:
- Triple-negative breast cancer (TNBC) is aggressive with poor prognosis and limited treatment options.
- Post-surgical recurrence and metastasis remain significant challenges in TNBC management.
- Current immunotherapies, including immune checkpoint blockade, show suboptimal responses in TNBC.
Purpose of the Study:
- To develop a cryogel-based dendritic cell (DC) immunotherapy to enhance post-surgical anti-tumor immunity in TNBC.
- To investigate the efficacy of a combined therapeutic approach involving gold nanodot-lipopolysaccharide (AuLPS)-loaded DCs, doxorubicin (Dox), and PD-1 immune checkpoint blockade (aPD-1+Dox+AuLPS@DC).
Main Methods:
- Fabrication of a cryogel matrix for sustained, localized delivery of therapeutic agents at the surgical site.
- Loading DCs with AuLPS nanoparticles to optimize adjuvant activity and enhance DC immunotherapy.
- Co-delivery of doxorubicin (Dox) and anti-PD-1 (aPD-1) with AuLPS-loaded DCs within the cryogel.
- Evaluation of DC viability, migration, functionality, and T-cell activation in tumor-draining lymph nodes and tumor beds.
- Assessment of therapeutic outcomes in an orthotopic TNBC mouse model, including tumor recurrence, metastasis, and survival.
Main Results:
- The cryogel formulation preserved DC viability and functionality, promoting sustained release of therapeutic agents.
- AuLPS nanoparticles enhanced DC activation and Th1 adjuvant activity, improving immunotherapy efficacy.
- The combined aPD-1+Dox+AuLPS@DC cryogel significantly boosted T-cell responses in both lymph nodes and tumor sites.
- Post-surgical administration of the cryogel immunotherapy markedly delayed tumor recurrence and reduced distant metastasis.
- Significant prolongation of survival was observed in the treated TNBC mouse model.
Conclusions:
- Cryogel-based DC immunotherapy offers a promising strategy for enhancing post-surgical anti-tumor immunity in TNBC.
- The combination of AuLPS-loaded DCs, doxorubicin, and immune checkpoint blockade within a cryogel matrix effectively combats TNBC recurrence and metastasis.
- This approach holds potential for improving therapeutic outcomes and survival rates in patients with triple-negative breast cancer.
